文献速递肝病

ADAPT、FIB-4与APRI在CENTAUR筛查人群中预测肝纤维化及NASH的比较

Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
PubMed 文献 · J Hepatol · 2021-08-27

在CENTAUR IIb期研究筛查人群中验证PRO-C3及ADAPT对中/重度纤维化和NASH的诊断性能;共517例有匹配活检和PRO-C3数据的成人NASH患者纳入。PRO-C3随纤维化及NASH活动指标加重而升高,ADAPT在预测进展性纤维化和NASH上优于FIB-4、APRI及AST/ALT比值。

要点

  • PRO-C3水平随纤维化分期、小叶炎症、气球样变及NAS评分增加而逐步升高。
  • PRO-C3可区分NAFL与NASH,且校正临床混杂因素后独立关联纤维化和NASH。
  • ADAPT预测进展性纤维化和NASH优于FIB-4、APRI及AST/ALT比值(p<0.001)。

核心结论

  • PRO-C3与NAFLD活动度评分及纤维化相关,ADAPT在检测NASH上优于其他无创评分。

研究设计与样本

  • 基于IIb期CENTAUR研究(NCT02217475)筛查人群的验证分析,纳入517例有匹配活检和PRO-C3测量的成人NASH伴肝纤维化患者。
  • 评估PRO-C3与NASH组织学特征关系,并用ROC分析和logistic回归估计PRO-C3单独或纳入ADAPT识别F≥2和NASH的诊断能力。

主要发现

  • PRO-C3≥20.2 ng/ml患者胰岛素、HOMA-IR、ALT、AST、碱性磷酸酶及血小板计数较低PRO-C3者升高(p<0.05)。
  • PRO-C3随肝纤维化、小叶炎症、肝细胞气球样变、脂肪变及NAFLD活动度评分增加而逐步升高(p<0.05)。
  • PRO-C3可区分NAFL与NASH(p<0.0001),且校正临床混杂因素后独立关联纤维化和NASH。
  • ADAPT预测进展性纤维化和NASH优于FIB-4、AST/血小板比值指数及AST/ALT比值(p<0.001)。

关键数值与推荐

  • PRO-C3高水平的截断值为≥20.2 ng/ml。
  • 诊断性能比较的结局为F≥2纤维化和NASH。

临床怎么用

  • PRO-C3和ADAPT可作为诊断工具,用于识别适合纳入临床试验的NASH患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The development of accurate non-invasive tests to detect and measure the extent of fibrosis and disease activity in patients with non-alcoholic steatohepatitis (NASH) - the progressive phenotype of non-alcoholic fatty liver disease (NAFLD) - is of great clinical importance. Herein, we aimed to validate the performance of PRO-C3 and ADAPT for the detection of moderate/severe fibrosis within the CENTAUR screening population. METHODS: PRO-C3 was assessed in plasma from the screening population of the phase IIb CENTAUR study (NCT02217475) in adults with NASH and liver fibrosis. The relation between PRO-C3 and histologic features of NASH was evaluated, as well as the demographics of patients with high and low levels of PRO-C3. The diagnostic ability of PRO-C3, as a standalone marker or incorporated into ADAPT, to identify patients with F≥2 and NASH was estimated using receiver-operating characteristic analysis and logistic regression models. RESULTS: A total of 517 individuals with matched biopsy and PRO-C3 measurements were included. Patients with PRO-C3 levels ≥20.2 ng/ml showed increased levels of insulin, HOMA-IR, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and platelet count compared to patients with low PRO-C3 (p <0.05). PRO-C3 increased stepwise with increasing liver fibrosis, lobular inflammation, hepatocyte ballooning, steatosis, and NAFLD activity score (p <0.05), and could distinguish between NAFL and NASH (p <0.0001). PRO-C3 was independently associated with fibrosis and NASH when adjusted for clinical confounders. ADAPT outperformed Fibrosis-4, AST-to-platelet ratio index, and AST/ALT ratio as a predictor of advanced fibrosis and NASH (p <0.001). CONCLUSION: PRO-C3 was associated with NAFLD activity score and fibrosis. ADAPT outperformed other non-invasive scores for detecting NASH. These data support the use of PRO-C3 and ADAPT as diagnostic tools to identify patients with NASH eligible for inclusion in clinical trials. CLINICAL TRIAL NUMBER: NCT02217475 LAY SUMMARY: PRO-C3 is a serological biomarker associated with liver disease activity and fibrosis. Its performance for the detection of disease activity and fibrosis is improved when it is incorporated into the ADAPT score. Herein, we showed that ADAPT was better at selecting patients with non-alcoholic steatohepatitis for inclusion in clinical trials than other non-invasive scores.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Nielsen MJ, Leeming DJ, Goodman Z, et al. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. J Hepatol. 2021. PMID: 34454994. doi:10.1016/j.jhep.2021.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。